San Diego-based biotechnology firm Cidara Therapeutics reported highly positive Phase IIb results for its long-acting antiviral biologic, CD-388, showing strong prevention efficacy against seasonal influenza in healthy adults aged 18-64. The randomized, double-blind trial demonstrated statistically significant protection across three dosing groups over a six-month period, with maintenance of efficacy confirmed at temperature-specific thresholds and excellent safety and tolerability profiles. This breakthrough positions CD-388 as a promising alternative to traditional flu vaccines and antivirals, potentially transforming seasonal influenza prophylaxis. The company plans regulatory discussions with the FDA to advance into pivotal trials, reflecting strong investor confidence as shares surged up to 95% on the news.